Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 49
Filter
Add more filters

Publication year range
1.
Actas Dermosifiliogr ; 114(1): 39-48, 2023 Jan.
Article in English, Spanish | MEDLINE | ID: mdl-35905817

ABSTRACT

Numerous surgical and nonsurgical modalities are available to treat basal cell carcinoma (BCC), but their true effectiveness and safety is unknown. This article summarizes the evidence presented in a recent Cochrane review and aims to facilitate the interpretation of the review's findings for the Spanish and Latin American scientific communities. Much of the evidence the reviewers found came from single studies, preventing meta-analysis. Conventional surgical excision continues to be the most effective treatment for low-risk BCC. Most studies had small sample sizes, and some had problems with blinding, limitations which will have affected the assessment of subjective outcomes, such as pain and cosmetic results. The authors identified a lack of standardization in relation to recurrences and cosmetic outcomes that threatens not only the internal validity of the studies but also their external validity and reproducibility.


Subject(s)
Carcinoma, Basal Cell , Skin Neoplasms , Humans , Carcinoma, Basal Cell/surgery , Pain , Reproducibility of Results , Skin Neoplasms/surgery
2.
Br J Dermatol ; 181(4): 770-777, 2019 10.
Article in English | MEDLINE | ID: mdl-30729508

ABSTRACT

BACKGROUND: In recent years, the need for international, objective, patient-reported outcomes measures has grown as international collaboration has increased. As most quality-of-life scales have been developed in English, there is a growing need to adapt them transculturally to obtain equivalence between the original instrument and the adapted scale. OBJECTIVES: To assess the construct and convergent-discriminant validity and responsiveness of the Colombian version of Skindex-29. METHODS: The cross-sectional and longitudinal validity and responsiveness were tested in both healthy and dermatology patients. Construct validity was tested through a confirmatory factor analysis. The convergent-discriminant validity was assessed by examining the Spearman correlation coefficient. Change sensitivity was tested by means of the standardized response mean. The effect size and the minimum detectable change were also assessed. RESULTS: A total of 265 participants were included; 21·1% were healthy individuals, and 78·9% patients had either inflammatory or noninflammatory skin diseases. Confirmatory factor analysis showed an adequate comparative fit index and Tucker-Lewis index adjustment for the root mean square error of approximation. Convergent validity showed moderate correlations between the emotions, functioning and physical function or physical role domains. Discriminant validity showed low correlations between overall domains for both scales. Sensitivity to change at the first and third month showed effect sizes in global Skindex scores of 0·92 and 0·82, respectively. CONCLUSIONS: The Colombian version of Skindex-29 is a valid and clinically sensitive instrument, which can be used for clinical practice and for research to measure the impact of skin diseases on the quality of life of dermatology patients.


Subject(s)
Patient Reported Outcome Measures , Quality of Life , Skin Diseases/diagnosis , Adolescent , Adult , Aged , Colombia , Cross-Sectional Studies , Female , Healthy Volunteers , Humans , Longitudinal Studies , Male , Middle Aged , Prospective Studies , Psychometrics/methods , Reproducibility of Results , Skin Diseases/psychology , Translations , Young Adult
5.
Am J Transplant ; 18(1): 197-206, 2018 01.
Article in English | MEDLINE | ID: mdl-28649744

ABSTRACT

Mannose-binding lectin (MBL) is synthesized by the liver and binds to microbes. MBL2 gene polymorphisms produce intermediate/low/null or normal MBL serum levels (MBL-deficient or MBL-sufficient phenotypes, respectively). We aimed to evaluate the incidence and severity of infection, rejection, and survival within 1 year after liver transplantation (LT) according to donor and recipient MBL2 gene polymorphisms. A repeated-event analysis for infection episodes (negative binomial regression, Andersen-Gill model) was performed in 240 LTs. Four hundred twenty-eight infectious episodes (310 bacterial, 15 fungal, 65 cytomegalovirus [CMV]-related, and 38 viral non-CMV-related episodes) and 48 rejection episodes were recorded. The main bacterial infections were urinary (n = 82, 26%) and pneumonia (n = 69, 22%). LT recipients of MBL-deficient livers had a higher risk of bacterial infection (incidence rate ratio [IRR] 1.48 [95% confidence interval 1.04-2.09], p = 0.028), pneumonia (IRR 2.4 [95% confidence interval 1.33-4.33], p = 0.013), and septic shock (IRR 5.62 [95% confidence interval 1.92-16.4], p = 0.002) compared with recipients of MBL-deficient livers. The 1-year bacterial infection-related mortality was higher in recipients of MBL-deficient versus MBL-sufficient livers (65.8% vs. 56.1%, respectively; p = 0.0097). The incidence of rejection, viral, or fungal infection was similar in both groups. Recipient MBL2 genotype did not significantly increase the risk of bacterial infection. LT recipients of MBL-deficient livers have a higher risk of bacterial infection, pneumonia, septic shock, and 1-year bacterial infection-related mortality after LT.


Subject(s)
Bacterial Infections/mortality , Graft Rejection/mortality , Liver Transplantation/mortality , Mannose-Binding Lectin/genetics , Polymorphism, Genetic , Postoperative Complications , Tissue Donors , Adult , Aged , Bacterial Infections/etiology , Bacterial Infections/pathology , Female , Follow-Up Studies , Genetic Predisposition to Disease , Genotype , Graft Rejection/etiology , Graft Rejection/pathology , Graft Survival , Humans , Liver Transplantation/adverse effects , Male , Mannose-Binding Lectin/deficiency , Middle Aged , Prognosis , Prospective Studies , Risk Factors , Survival Rate
6.
Actas Dermosifiliogr ; 108(3): 244-252, 2017 Apr.
Article in English, Spanish | MEDLINE | ID: mdl-28063525

ABSTRACT

INTRODUCTION: To date, no formal study has been published regarding how Colombian patients with skin disorders could be affected according to their perception of disease. OBJECTIVE: To determine the impact in quality of life of skin diseases in a Colombian population. METHODS: This multicenter study included patients with skin disease from almost the whole country. Individuals >18 years old; of any gender; with any skin disease and who signed informed consent, were included. We applied the Colombian validated version of the Skindex-29 instrument. RESULTS: A total of 1896 questionnaires had sufficient information for the analyses. No significant differences in sociodemographic characteristics of patients who returned the questionnaire incomplete vs. complete, were found. Participants mean age was 41.5 years. There were no statistical differences in men vs. women regarding the global (p=0.37), symptoms (p=0.71) and emotions (p=0.32) domains, whereas statistical differences were found in the function domain (p=0.04; Mann-Whitney U test). Psoriasis, contact dermatitis, atopic dermatitis, urticaria, hair disorders, Hansen's disease, scars, hyperhidrosis and genital human papillomavirus disease scored the highest. LIMITATIONS: Skindex-29 score variability as a result of differences in the location of the skin lesions, their inflammatory or non-inflammatory nature, and the start of therapy. CONCLUSIONS: Even the most localized or asymptomatic skin lesion in our population leads to a disruption at some level of patient's wellness. This study adds well supported scientific data of the burden of skin diseases worldwide.


Subject(s)
Quality of Life , Skin Diseases , Adolescent , Adult , Cross-Sectional Studies , Diagnostic Self Evaluation , Female , Humans , Male , Middle Aged , Skin Diseases/psychology , Young Adult
7.
J Eur Acad Dermatol Venereol ; 30(1): 8-15, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26552049

ABSTRACT

Conventional PDT (c-PDT) is a widely used and approved non-invasive treatment for actinic keratosis (AK). Recent clinical, histological and immunohistochemical observations have shown that c-PDT with methyl aminolevulinate (MAL) may also partially reverse the signs of photodamage. However, pain and the need for special light source equipment are limiting factors for its use, especially in the treatment of large areas. More recently, daylight PDT (DL-PDT) has been shown to be similar to c-PDT in the treatment of AK, nearly painless and more convenient to perform. To establish consensus on recommendations for the use of MAL DL-PDT in patients with large-scale photodamaged skin. The expert group was comprised of eight dermatologists. Consensus was developed based on the personal experience of the experts in c-PDT and DL-PDT, and results of an extensive literature review. MAL DL-PDT for large areas of photodamaged skin was evaluated and recommendations based on broad clinical experience were provided. As supported by evidence-based data from multicentre studies conducted in Australia and Europe, the authors defined the concept of 'actinic field damage' which refers to photodamage associated with actinic epidermal dysplasia, and provide comprehensive guidelines for the optimal use of DL-PDT in the treatment of actinic field damage. The authors concluded that MAL DL-PDT has a similar efficacy to c-PDT at 3-month (lesion complete response rate of 89% vs. 93% in the Australian study and 70% vs. 74% in the European study (95% C.I. = [-6.8;-0.3] and [-9.5;2.4] respectively) and 6-month follow-ups (97% maintenance of complete lesion response) in the treatment of AKs. The authors agree that DL-PDT is not only efficacious but also nearly pain-free and easy to perform, and therefore results in high patient acceptance especially for the treatment of areas of actinic field damage.


Subject(s)
Aminolevulinic Acid/analogs & derivatives , Keratosis, Actinic/drug therapy , Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Administration, Topical , Aminolevulinic Acid/therapeutic use , Consensus , Europe , Humans
8.
Actas Dermosifiliogr ; 107(1): 44-54, 2016.
Article in English, Spanish | MEDLINE | ID: mdl-26546026

ABSTRACT

INTRODUCTION: The value of randomized clinical trials (RCTs) undertaken to identify an association between an intervention and an outcome is determined by their quality and scientific rigor. OBJECTIVE: To assess the methodological quality of RCTs published in Spanish-language dermatology journals. METHODS: By way of a systematic manual search, we identified all the RCTs in journals published in Spain and Latin America between 1997 (the year in which the CONSORT statement was published) and 2012. Risk of bias was evaluated for each RCT by assessing the following domains: randomization sequence generation, allocation concealment, blinding of patients and those assessing outcomes, missing data, and patient follow-up. Source of funding and conflict of interest statements, if any, were recorded for each study. RESULTS: The search identified 70 RCTs published in 21 journals. Most of the RCTs had a high risk of bias, primarily because of gaps in the reporting of important methodological aspects. The source of funding was reported in only 15 studies. DISCUSSION AND CONCLUSIONS: In spite of the considerable number of Spanish and Latin American journals, few RCTs have been published in the 15 years analyzed. Most of the RCTs published had serious defects in that the authors omitted methodological information essential to any evaluation of the quality of the trial and failed to report sources of funding or possible conflicts of interest for the authors involved. Authors of experimental clinical research in dermatology published in Spain and Latin America need to substantially improve both the design of their trials and the reporting of results.


Subject(s)
Dermatology , Periodicals as Topic , Randomized Controlled Trials as Topic/standards , Humans , Research Design , Spain
9.
Actas Dermosifiliogr ; 107(3): 224-34, 2016 Apr.
Article in English, Spanish | MEDLINE | ID: mdl-26643786

ABSTRACT

BACKGROUND: Daylight PDT (dPDT) is easy to use and does not require light equipment. Such therapy has been exhaustively proved to be successful in the treatment of actinic keratosis, but its use in skin photodamage remains unclear. OBJECTIVE: To evaluate dPDT's efficacy in skin facial photodamage. PATIENTS AND METHODS: This was a parallel-group double-blind, randomized placebo-controlled trial. Sixty participants with symmetric facial photodamage were allocated to topical methyl aminolevulinate (MAL) and daylight vs. matching placebo and daylight. Primary outcome was global photodamage improvement/failure 1 month after the third session. Secondary outcomes included: pain evaluation; specific photodamage severity scores; sun irradiance quantification and Skindex-29 scores. Adverse events were also investigated. RESULTS: Primary analysis included all randomized patients. All patients sun-exposed for 120min in 3 sessions. The risk of failure was lower in the MAL-dPDT group than in the placebo plus daylight group (RR: 0.18; 95% CI: 0.08-0.41). Mean solar irradiance (W/m(2)) during the first, second and third sessions was 480.82, 430.07 and 435.84, respectively. Items 5 and 14 of Skindex-29 in the MAL-dPDT group showed statistical significant differences. Two patients in the MAL-dPDT group had serious and non-serious events not directly related to the product. CONCLUSION: dPDT with MAL was un-painful, effective and safe for the treatment of facial photodamage. Herpes simplex prophylaxis should be considered before sessions.


Subject(s)
Aminolevulinic Acid/analogs & derivatives , Photochemotherapy , Photosensitizing Agents/therapeutic use , Skin Aging/radiation effects , Sunlight , Aminolevulinic Acid/therapeutic use , Double-Blind Method , Humans
10.
Am J Transplant ; 15(4): 1021-7, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25676738

ABSTRACT

We sought to determine the frequency, risk factors, and clinical impact of recurrent urinary tract infections (UTI) in kidney transplant recipients. Of 867 patients who received a kidney transplant between 2003 and 2010, 174 (20%) presented at least one episode of UTI. Fifty-five patients presented a recurrent UTI (32%) and 78% of them could be also considered relapsing episodes. Recurrent UTI was caused by extended-spectrum betalactamase (ESBL)-producing Klebsiella pneumoniae (31%), followed by non-ESBL producing Escherichia coli (15%), multidrug-resistant (MDR) Pseudomonas aeruginosa (14%), and ESBL-producing E. coli (13%). The variables associated with a higher risk of recurrent UTI were a first or second episode of infection by MDR bacteria (OR 12; 95%CI 528), age >60 years (OR 2.2; 95%CI 1.15.1), and reoperation (OR 3; 95%CI 1.37.1). In addition, more relapses were recorded in patients with UTI caused by MDR organisms than in those with susceptible microorganisms. There were no differences in acute rejection, graft function, graft loss or 1 year mortality between groups. In conclusion, recurrent UTI is frequent among kidney recipients and associated with MDR organism. Classic risk factors for UTI (female gender and diabetes) are absent in kidney recipients, thus highlighting the relevance of uropathogens in this population.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Drug Resistance, Microbial , Kidney Transplantation , Urinary Tract Infections/drug therapy , Female , Humans , Male , Middle Aged , Recurrence , Urinary Tract Infections/physiopathology
11.
Actas Dermosifiliogr ; 106(5): 415-22, 2015 Jun.
Article in English, Spanish | MEDLINE | ID: mdl-25765504

ABSTRACT

INTRODUCTION: The necessary foundation for good clinical practice lies in knowledge derived from clinical research. Evidence from randomized clinical trials (RCTs) is the pillar on which decisions about therapy are based. OBJECTIVE: To search exhaustively and rigorously to identify RCTs in dermatology journals published in Spanish. METHODS: We located dermatology journals through the following search engines and indexes: PubMed, LILACS, SciELO, Periódica, Latindex, Índice Médico Español, C-17, IBECS, EMBASE, and IMBIOMED. We also sought information through dermatology associations and dermatologists in countries where Spanish was the usual language of publication, and we searched the Internet (Google). Afterwards we searched the journals electronically and manually to identify RCTs in all available volumes and issues, checking from the year publication started through 2012. RESULTS: Of 28 journals identified, we included 21 in the search. We found a total of 144 RCTs published since 1969; 78 (54%) were in Latin American journals and 66 (46%) were in Spanish journals. The most frequent disease contexts for RCTs in Spanish journals were psoriasis, mycoses, and acne vulgaris. In Latin American journals, the most frequent disease contexts were common warts, mycoses, acne vulgaris, and skin ulcers on the lower limbs. Manual searches identified more RCTs than electronic searches. CONCLUSIONS: Manual searches found a larger number of RCTs. Relatively fewer RCTs are published in Spanish and Latin American journals than in English-language journals. Internet facilitated access to full texts published by many journals; however, free open access to these texts is still unavailable and a large number of journal issues are still not posted online.


Subject(s)
Dermatology , Periodicals as Topic , Randomized Controlled Trials as Topic , Bibliometrics , Databases, Bibliographic , Internet , PubMed , Spain
12.
Transpl Infect Dis ; 16(4): 631-3, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24903646

ABSTRACT

Toxoplasma gondii is an opportunistic pathogen that causes neurologic and extraneurologic manifestations in immunosuppressed patients. Encephalitis and intracranial mass lesions are easily recognized as typical manifestations of toxoplasmosis. However, meningitis caused by T. gondii is a rare condition with very few cases described in the literature. We present the case of a heart transplant recipient who developed toxoplasmic encephalitis associated with meningitis. After an extensive review of the medical literature, we found only 1 case of meningitis in solid organ transplant recipients and <25 cases in immunosuppressed patients, such as patients infected with human immunodeficiency virus or those with Hodgkin's disease. In this report, we consider toxoplasmosis in the differential diagnosis of meningitis in immunocompromised individuals.


Subject(s)
Encephalitis/parasitology , Heart Transplantation/adverse effects , Meningitis/parasitology , Toxoplasmosis, Cerebral/etiology , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/therapeutic use , Clindamycin/administration & dosage , Clindamycin/therapeutic use , Drug Therapy, Combination , Humans , Male , Meningitis/complications , Middle Aged , Protein Synthesis Inhibitors/administration & dosage , Protein Synthesis Inhibitors/therapeutic use , Pyrimethamine/administration & dosage , Pyrimethamine/therapeutic use , Toxoplasmosis, Cerebral/parasitology
13.
Transpl Infect Dis ; 16(2): 324-8, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24456244

ABSTRACT

Anti-Pneumocystis prophylaxis is recommended for at least 6-12 months after solid organ transplantation, as most cases of Pneumocystis jirovecii pneumonia (PCP) occur during the first year post transplantation. Herein, we report 4 cases of late-onset PCP (>1 year post transplant). PCP appeared in a range of 50-68 months post transplant. Two cases had history of humoral rejection episodes treated with rituximab, and the other 2 had low CD4+ T-cell count (<200 cells/mm(3) ) at the time of diagnosis. All 4 patients survived. In conclusion, although the number of cases is low, we must be aware of the possibility of late-onset PCP in solid organ transplant patients. The role of previous use of rituximab or persistent CD4+ T-cell lymphopenia should be addressed in future studies.


Subject(s)
Anti-Infective Agents/therapeutic use , Organ Transplantation/adverse effects , Pneumocystis carinii , Pneumonia, Pneumocystis/drug therapy , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Adult , Female , Humans , Male , Middle Aged , Pneumonia, Pneumocystis/diagnosis , Pneumonia, Pneumocystis/microbiology , Time Factors
14.
Transpl Infect Dis ; 16(6): 951-7, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25318640

ABSTRACT

BACKGROUND: Invasive aspergillosis (IA) has been considered an infrequent complication after renal transplantation. We aimed to evaluate the differences in clinical and epidemiologic characteristics of IA between renal and other types of transplantation. METHODS: We reviewed all cases of solid organ transplant (SOT) recipients from Hospital Clinic at Barcelona, who had proven and probable IA, according to the EORTC/MSG criteria, between June 2003 and December 2010. RESULTS: A total of 1762 transplants were performed. From this cohort, 27 cases of IA were diagnosed (1.5%): in 56% (15/27) liver, 33% (9/27) kidney, and 11% (3/27) combined transplant. The median onset time from renal and non-renal transplants to IA was 217 and 10 days, respectively (P < 0.001). There were 6 cases (22%) of late IA (>6 months), all in kidney recipients (P < 0.001). Renal transplant patients with IA more frequently had chronic lung disease (44% vs. 6%) and chronic heart failure (33% vs. 6%); they also had none of the classical risk factors for IA defined for liver transplantation (0% vs. 33%, P = 0.001), and therefore they did not receive antifungal prophylaxis (0% vs. 72%, P = 0.001). In 14/24 patients, serum galactomannan antigen was positive, and this related to higher mortality. CONCLUSIONS: While classical risk factors described for IA in liver recipients are still valid, IA appears later in renal patients and is commonly associated with co-morbid conditions.


Subject(s)
Aspergillosis/diagnosis , Kidney Transplantation/adverse effects , Aspergillosis/pathology , Female , Humans , Male , Middle Aged , Retrospective Studies , Risk Factors , Treatment Outcome
16.
Clin Exp Dermatol ; 37(4): 379-86, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22582911

ABSTRACT

BACKGROUND: Improvement in the morphological appearance of collagen and elastic fibres has been reported after the use of trichloroacetic acid, dermabrasion and laser therapy, but the histopathological changes occurring after photodynamic therapy are less understood. AIM: To assess the histological changes that occur after methyl aminolevulinate (MAL) plus red-light therapy for facial photodamage. METHODS: This was a prospective, double-blind, double-arm, randomized, placebo-controlled trial of MAL plus red light in patients with facial photodamage. A 3-mm punch biopsy was taken from each side of the face before randomization and start of therapy. A dermatopathologist blinded to the treatment assessed epidermal and dermal layer thickness, perivascular inflammation, solar elastosis, perifollicular fibrosis, telangiectasias, number of elastic and collagen fibres, and grade of reticular degeneration. RESULTS: In total, 65 women were initially screened for eligibility, but skin samples from only 38 of these were analysed. The change in dermal thickness from baseline to postintervention was significant (P < 0.01, Wilcoxon signed rank test). Although there was a trend for the epidermis to be thinner after MAL plus red light vs. placebo plus red light (46.25 µm vs. 55.50 µm, respectively), the difference was not significant (P = 0.64, Mann-Whitney U-test). Similarly, the changes in dermal thickness obtained with the two treatments were not significant (P = 0.99, Mann-Whitney test). Histological improvement was seen using stains for collagen, elastic tissue, and perifollicular fibrosis after MAL plus red light therapy. DISCUSSION: Dermal thickness increased after the use of MAL plus red light, and there was improvement in collagen, elastic tissue and perifollicular fibrosis. Although these differences were not significant, most of the histopathological features examined in our study improved after treatment with MAL plus red light. The lack of significance might be due either to the low power of this study or to the failure of our scoring method to detect significant histopathological differences.


Subject(s)
Aminolevulinic Acid/analogs & derivatives , Facial Dermatoses/drug therapy , Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Skin Aging/drug effects , Skin Aging/radiation effects , Adult , Aged , Aminolevulinic Acid/therapeutic use , Collagen , Double-Blind Method , Elastic Tissue , Face/radiation effects , Facial Dermatoses/etiology , Female , Humans , Middle Aged , Prospective Studies
17.
Transpl Infect Dis ; 13(6): 598-607, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21535336

ABSTRACT

BACKGROUND: Information concerning the risk factors and outcome of late infection (LI) after solid organ transplantation (SOT) still remains scarce. METHODS: We prospectively analyzed all patients undergoing SOT from July 2003 to March 2008, who survived the first 6 months after surgery and with a minimum 1-year follow-up. Risk factors associated with the development of bacterial and cytomegalovirus (CMV) LI and survival were identified. RESULTS: Overall, 942 SOT recipients (491 kidney, 280 liver, 65 heart, and 106 double transplants) were included. During the study period 147 patients (15.6%) developed 276 episodes of LI (incidence rate, 0.43 per 1000 transplantation-days). Bacteria were the most prevalent etiology (88.0%). Primary sources of infection included urinary tract (36.9%), intra-abdominal (16.7%), and sepsis without source (13.4%). Independent risk factors for late bacterial infection were: age (hazard ratio [HR] [per year] 1.0; 95% confidence interval [CI]: 1.0-1,0), female gender (HR 1.7; 95%CI: 1.1-2.6), anti-hepatitis C virus (HCV) positive serostatus (HR 1.8; 95%CI: 1.1-3.0), chronic allograft dysfunction (HR 3.2; 95%CI: 1.7-6.1), early CMV disease (HR 2.2; 95%CI 1.2-4.1), and early bacterial infection (HR 2.5; 95%CI 1.6-3.8). The occurrence of chronic allograft dysfunction was an independent risk factor for late CMV disease (HR 6.5; 95%CI: 1.7-24.6), whereas immunosuppression based on mammalian target of rapamycin inhibitors protected against the development of late CMV disease (HR 0.3; 95%CI: 0.1-1.0). Cox model selected anti-HCV positive serostatus (adjusted HR [aHR] 2.67; 95%CI: 1.27-5.59), age (aHR [per year] 1.06; 95%CI: 1.02-1.10), and the occurrence of LI (aHR 9.12; 95%CI: 3.90-21.33) as independent factors for mortality. CONCLUSIONS: LI did not constitute an uncommon complication in our cohort, and patients at risk may benefit from close clinical monitoring.


Subject(s)
Immunosuppressive Agents/adverse effects , Opportunistic Infections/complications , Opportunistic Infections/epidemiology , Organ Transplantation , Postoperative Complications , Adult , Bacterial Infections/complications , Bacterial Infections/epidemiology , Cohort Studies , Cytomegalovirus , Cytomegalovirus Infections/epidemiology , Female , Humans , Male , Middle Aged , Mycoses/complications , Mycoses/epidemiology , Parasitic Diseases/complications , Parasitic Diseases/epidemiology , Prospective Studies , Risk Factors , Spain/epidemiology , Virus Diseases/complications , Virus Diseases/epidemiology
18.
J Eur Acad Dermatol Venereol ; 25(1): 49-58, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20456545

ABSTRACT

BACKGROUND: To date, there is no gold standard therapy for skin photoageing. In the last decade, laser technologies have offered great promise among skin-rejuvenation therapies; however, both non-ablative and ablative fractional resurfacing modalities have their own benefits and drawbacks. More recently, open-label studies and few controlled trials have suggested that photodynamic therapy may have therapeutic potential in photodamage. OBJECTIVE: To assess the efficacy of methyl aminolevulinate + red-light on facial photodamage in a double-blind split-face randomized placebo-controlled trial. METHODS: Subjects had initially two split-face treatments 2-3 weeks apart in which half of the face was treated with MAL + red-light compared with placebo + red-light. Primary outcome was the assessment of global photodamage 1 month after session 2. Secondary outcomes included the assessment of fine lines, mottled pigmentation, tactile roughness, sallowness, erythema and telangiectasia 1 month after session 2, according to severity scores rated as failure, improvement or success. RESULTS: Based on the intention-to-treat analysis, a total of 48 patients (96 split-faces) were included. Facial global photodamage success or improvement had occurred in 94 split-faces and in no split-faces receiving placebo (RR: 0.02; 95% confidence interval, 0.0-0.14; P = 0.0000). One patient had an adverse event that led to the discontinuation of the therapy after session 1. CONCLUSIONS: Methyl aminolevulinate + red-light demonstrated significantly superior efficacy in global facial photodamage compared with placebo. This therapy was also useful for all other specific secondary outcomes, except for telangiectasia. Overall, MAL + red-light sessions were well tolerated and resulted in high/total patient satisfaction in the majority of subjects (80.4%).


Subject(s)
Aminolevulinic Acid/analogs & derivatives , Face , Phototherapy , Skin Aging/drug effects , Adult , Aminolevulinic Acid/adverse effects , Aminolevulinic Acid/pharmacology , Aminolevulinic Acid/therapeutic use , Double-Blind Method , Female , Humans , Middle Aged , Phototherapy/adverse effects , Placebos , Prospective Studies , Skin Aging/radiation effects
19.
Clin Exp Dermatol ; 35(6): 658-63, 2010 Aug.
Article in English | MEDLINE | ID: mdl-19874354

ABSTRACT

BACKGROUND: Onychomycosis is one of the commonest dermatological diseases worldwide. The antifungal activity of current medications varies, and treatment failure occurs in 25-40% of treated patients. AIMS: To evaluate the in vitro antifungal activity of itraconazole, fluconazole, terbinafine and voriconazole against isolates taken from patients with onychomycosis. METHODS: Nail isolates were evaluated according to methods described in the protocols of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST) and the Clinical and Laboratory Standards Institute (CLS M38-A), and a CLSI M38-A modified technique for dermatophytes. Antifungal agents tested included terbinafine, itraconazole, voriconazole and fluconazole. RESULTS: In total, 103 isolates of Candida species (n = 58), Fusarium species (n = 10), Fusicoccum dimidiatum (n = 4), Scytalidium hyalinum (n = 1) and dermatophytes (n = 30) were evaluated. Itraconazole and voriconazole were the most active agents against Candida species, whereas terbinafine and voriconazole were most potent against dermatophytes. Fusarium species had the highest minimum inhibitory concentration (MIC) values with all antifungal agents. CONCLUSIONS: The aetiological agents of onychomycosis that we found differ from those found in other countries, suggesting that the heat and humidity of the Colombian climate could favour yeast nail infections. The lowest MICs for Candida species (obtained with voriconazole, followed by itraconazole) may be explained by emerging resistant strains. Against dermatophytes, the lowest MICs were obtained with terbinafine, followed by voriconazole. MIC values for the evaluated agents were higher for non-dermatophyte filamentous fungi than for other fungi. As MIC breakpoints have not yet been established for onychomycosis therapies, it remains unclear if in vitro activities of antifungal drugs are predictive of clinical outcome. Well-designed clinical studies are necessary to assist clinicians in choosing the best antifungal agents.


Subject(s)
Antifungal Agents/pharmacology , Fungi/drug effects , Onychomycosis/drug therapy , Analysis of Variance , Arthrodermataceae/drug effects , Candida/drug effects , Colombia , Dose-Response Relationship, Drug , Fluconazole/pharmacology , Fusarium/drug effects , Humans , Itraconazole/pharmacology , Microbial Sensitivity Tests , Naphthalenes/pharmacology , Onychomycosis/microbiology , Pyrimidines/pharmacology , Terbinafine , Triazoles/pharmacology , Voriconazole
20.
Rev Clin Esp ; 210(5): 209-15, 2010 May.
Article in Spanish | MEDLINE | ID: mdl-20381031

ABSTRACT

OBJECTIVES: To investigate the degree of burnout among resident physicians of a university hospital and the factors associated with it. MATERIALS AND METHODS: Maslach burnout Inventory (MBI) was sent to all residents, which assesses emotional exhaustion, depersonalization and personal accomplishment. Burnout exists when high degree of emotional exhaustion or depersonalization are obtained. Several variables were analyzed (age, sex, nationality, year of residency, speciality, total monthly calls and in emergency departments, days since last call, duty-free day after calls, position at calls). It's relationship with the score on the different dimensions of MBI and burnout was analyzed through the test of the chi-square, whereas the association between scores of MBI and the number of calls were analyzed using linear regression. RESULTS: 132 of 290 residents answered (45.5%): 40.2% had a high emotional exhaustion and a 64.4% presented depersonalization. In total, 69.7% of the residents had burnout. There was no statistically association between the epidemiological variables and the different dimensions of the MBI. The total number of calls per month were significantly associated with emotional exhaustion (p<0.05). There wasn't any relation to the number of calls in emergency departments. Resident physicians who had 5 or more calls per month showed burnout more often than the rest (76.6% versus 60.0%, p<0.05). A trend towards a higher burnout was present among residents of Internal medicine and medical specialities than the rest (75.6% versus 60.0%, p=0.05). CONCLUSIONS: The prevalence of burnout among the group of residents is high and relates mainly to the monthly number of calls.


Subject(s)
Burnout, Professional/epidemiology , Internship and Residency/statistics & numerical data , Workload/statistics & numerical data , Adult , Female , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL